Document is current
Any future updates will be listed below
-
Authors
Wan, Jonathan C. M. https://orcid.org/0000-0003-0001-1802
Stephens, Dennis
Luo, Lingqi
White, James R. https://orcid.org/0000-0002-7535-9179
Stewart, Caitlin M. https://orcid.org/0000-0002-5070-4810
Rousseau, Benoît https://orcid.org/0000-0002-1594-4827
Tsui, Dana W. Y.
Diaz, Luis A. Jr. https://orcid.org/0000-0002-7079-8914
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748)
EIF | Stand Up To Cancer (SU2C-AACR-DT22-17)
- License Information
-
More Information
Article History
Received: 17 September 2021
Accepted: 8 August 2022
First Online: 23 August 2022
Competing interests
: J.C.M.W. is an inventor of patents for methods for ctDNA detection. J.C.M.W. and L.A.D. filed provisional patent application “Detection of somatic mutational signatures from whole genome sequencing of cell-free DNA” (U.S. Provisional Patent Application Number 63/216,727) relating to this work. D.S. serves as a consultant for Pyxis, Jounce, and Memorial Sloan Kettering Cancer Center and is employed by the Dana-Farber Cancer Institute. J.R.W. is the founder and owner of Resphera Biosciences LLC, and serves as a consultant to MSKCC and Personal Genome Diagnostics Inc. B.R. has served in a consulting/advisory role for Bayer, Roche, Novartis, Gilead, Servier, and Neophore and has received travel expenses from Bayer, Servier, and Astellas. D.W.Y.T. received the following honoraria more than two years ago from Nanodigmbio, Cowen, and BoA Merrill Lynch; research funding from ThermoFisher Scientific, EPIC Sciences, Prostate Cancer Foundation; Travel, Accommodation, Expenses from Nanodigmbio. D.W.Y.T. is a co-inventor of “Systems and methods for detecting cancer via cfDNA screening” (WO2019204208A1) and “Systems and methods for distinguishing pathological mutations from clonal hematopoietic mutations in plasma cell-free DNA by fragment size analysis” (WO2021194837A1). D.W.Y.T. is currently an employee of PetDx. Inc. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. He is a compensated consultant to PGDx, 4Paws (PetDx), Innovatus CP, Se’er, Kinnate, and Neophore. He is an uncompensated consultant for Merck but has received research support for clinical trials from Merck. L.A.D. is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and L.A.D. He holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection, Se’er, Kinnate, and Neophore. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. L.L. and C.M.S. declare no competing interests.
